Company
Hinge Bio
Taking Antibodies to the Next Dimension
Also known as Hinge Bio, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Hinge Bio, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Hinge Bio’s GEM-DIMER™ platform was developed to create next-generation therapeutics for difficult to treat diseases.
Funding snapshot
- Total raised
- $66.8MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Series A, $30M2025-01-15
Funding rounds
- Series A
- $30M2025-01-15, Company stated
- Round, 2024
- $30.6M2024-12-31, SEC form D sold, 82 investors
- Round, 2020
- $18M2020-12-18, SEC form D sold, 77 investors
- Round, 2020
- $18.2M2020-02-11, SEC form D sold, 100 investors
Products
- Other
- HB2198
Loading relationship preview